Correspondence 0001493152-24-035690 from Vitro Biopharma, Inc. (VTRO) (CIK 0000793171)
Vitro Biopharma, Inc. (VTRO) (CIK 0000793171)
Date: Sept. 10, 2024 · CIK: 0000793171 · Accession: 0001493152-24-035690
AI Filing Summary & Sentiment
File numbers found in text: 333-267366
Letter
VIA EDGAR Division of Corporation Finance Office of Life Sciences Attention: Jessica Dickerson and Joe McCann File No. 333-267366 Request for Acceleration of Effectiveness Requested Date: Wednesday, September 11, 2024 Requested Time: 4:30 P.M. Eastern Time
Dear Ms. Dickerson and Mr. McCann:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), the undersigned, as representative of the several underwriters, hereby joins in the request of Vitro Biopharma, Inc. that the effective date of the above-referenced registration statement be accelerated so as to permit it to become effective at 4:30 p.m. Eastern time on Wednesday, September 11, 2024, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Act, the undersigned advise that there will be distributed to each underwriter and dealer, institutional investor, retail investor and any other who is reasonably anticipated to participate in the distribution of the securities, as many copies of the preliminary prospectus dated September 5, 2024 as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
Each of the undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
DOMINARI SECURITIES LLC
Show Raw Text
CORRESP
1
filename1.htm
Dominari
Securities LLC
725
Fifth Avenue
New
York NY 10022
September
10, 2024
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
Office
of Life Sciences
100
F Street, NE
Washington,
D.C. 20549
Attention:
Jessica Dickerson and Joe McCann
Re:
Vitro
Biopharma, Inc.
Registration
Statement on Form S-1
Filed
September 9, 2022, as amended
File
No. 333-267366
Request
for Acceleration of Effectiveness
Requested
Date: Wednesday, September 11, 2024
Requested
Time: 4:30 P.M. Eastern Time
Dear
Ms. Dickerson and Mr. McCann:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended (the “Act”), the undersigned, as representative of the several underwriters,
hereby joins in the request of Vitro Biopharma, Inc. that the effective date of the above-referenced registration statement be accelerated
so as to permit it to become effective at 4:30 p.m. Eastern time on Wednesday, September 11, 2024, or as soon thereafter as practicable.
Pursuant
to Rule 460 under the Act, the undersigned advise that there will be distributed to each underwriter and dealer, institutional investor,
retail investor and any other who is reasonably anticipated to participate in the distribution of the securities, as many copies of the
preliminary prospectus dated September 5, 2024 as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
Each
of the undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities
Exchange Act of 1934, as amended.
Very truly yours,
DOMINARI SECURITIES LLC
By:
/s/ Dr. Cosme Ordonez
Dr. Cosme Ordonez
Managing Director, Head of Investment Banking